Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo Dienstmann

Showing results (11-20 of 175) with videos related to

Pageof 18
Sort By:
Cancer Journal (Sudbury, Mass.)|June 25, 2016
Spectrum of Gene Mutations in Colorectal Cancer: Implications for TreatmentRodrigo Dienstmann, Josep Tabernero
Clinical Breast Cancer|November 10, 2006
Evidence-based neoadjuvant endocrine therapy for breast cancerRodrigo Dienstmann, Jose Bines
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal CancerRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Current Opinion in Oncology|March 16, 2013
Biomarker-driven patient selection for early clinical trialsRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginningRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Current Clinical Pharmacology|March 22, 2012
Application of monoclonal antibodies as cancer therapy in solid tumorsRodrigo Dienstmann, Ben Markman, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Cancer Journal (Sudbury, Mass.)|March 24, 2011
Molecular predictors of response to chemotherapy in colorectal cancerRodrigo Dienstmann, Eduardo Vilar, Josep Tabernero
Oncotarget|March 30, 2011
Personalizing therapy with targeted agents in non-small cell lung cancerRodrigo Dienstmann, Pablo Martinez, Enriqueta Felip
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patientsRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Pageof 18

Showing results (11-20 of 175) with videos related to

Sort By:
Pageof 18
Cancer Journal (Sudbury, Mass.)|June 25, 2016
Spectrum of Gene Mutations in Colorectal Cancer: Implications for TreatmentRodrigo Dienstmann, Josep Tabernero
Clinical Breast Cancer|November 10, 2006
Evidence-based neoadjuvant endocrine therapy for breast cancerRodrigo Dienstmann, Jose Bines
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal CancerRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Current Opinion in Oncology|March 16, 2013
Biomarker-driven patient selection for early clinical trialsRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginningRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Current Clinical Pharmacology|March 22, 2012
Application of monoclonal antibodies as cancer therapy in solid tumorsRodrigo Dienstmann, Ben Markman, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Cancer Journal (Sudbury, Mass.)|March 24, 2011
Molecular predictors of response to chemotherapy in colorectal cancerRodrigo Dienstmann, Eduardo Vilar, Josep Tabernero
Oncotarget|March 30, 2011
Personalizing therapy with targeted agents in non-small cell lung cancerRodrigo Dienstmann, Pablo Martinez, Enriqueta Felip
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patientsRodrigo Dienstmann, Ramon Salazar, Josep Tabernero
Pageof 18